However, it is still elusive whether pirfenidone is able to regulate Cav-1 expression in IPF, and Cav-1 expression in the therapeutic agent-treated IPF has not yet been investigated by other studies. Here, CAV1 is linked to idiopathic pulmonary fibrosis.